Cordium Links, a provider of centralized cardiac safety monitoring, has established a joint venture with a Chinese organization to deliver core lab services to drug development companies performing cardiac safety evaluation as part of clinical research in China.
The company said the joint venture, Lawke Links, will bring a full range of ECG core lab services, including project management, site support and centralized ECG data analysis to China. Lawke Links will provide FDA and ICH compliant cardiac safety analysis to biopharmaceutical companies conducting phase I - phase IV multinational clinical trials.
“We believe our drug development sponsors who are conducting clinical research in China will appreciate having state-of-the-art core lab services in country,” said Kurian Abraham, MD, Cordium CEO. “With infrastructure and expertise ready and available, we will be able to save companies significant time and money while providing them with more options.”
Lawke Links’ will donate 9 percent of the value of work performed on all its contracts through June of 2009 to support the reconstruction and humanitarian efforts associated with the China Earthquake, according to the Morganton, N.C.-based Cordium.
In addition to ECG core lab services, Lawke Links has established a relationship with Peking Union Lawke Biomedical Development Limited (PUL) to provide central lab services. PUL initially will head up project management and site support for Lawke Links in China, according to Jian Ho, MD, PhD, CEO and medical director of PUL.